Xtant Medical Holdings logo
Xtant Medical Holdings XTNT
$ 0.48 1.1%

Annual report 2025
added 03-31-2026

report update icon

Xtant Medical Holdings Financial Statements 2011-2026 | XTNT

Annual Financial Statements Xtant Medical Holdings

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

78.1 M 57.5 M 123 M 86.6 M 47.9 M 19.6 M 18.4 M 26.5 M 8.94 M 4.6 M 22.9 M 21.6 M 31.4 M 64.9 M 111 M

Shares

140 M 134 M 119 M 94.1 M 85.5 M 13.3 M 13.3 M 11.8 M 1.52 M 1.06 M 830 K 546 K 435 K 389 K 357 K

Historical Prices

0.56 0.43 1.03 0.92 0.56 1.2 1.6 1.61 6.84 6.6 33.6 36.4 60 150 343

Net Income

4.97 M -16.4 M 660 K -8.48 M -4.85 M -7.02 M -8.22 M -70.1 M -52.4 M -19.5 M -2.17 M -10.5 M -12.7 M -7.71 M -3.01 M

Revenue

134 M 117 M 91.3 M 58 M 55.3 M 53.3 M 64.7 M 72.2 M 82.6 M 90 M 59.3 M 35.3 M 33.1 M 33 M 30.1 M

Cost of Revenue

49.7 M 49.1 M 35.8 M 25.8 M 22.8 M 18.9 M 22.2 M 28.7 M 32.5 M 27.7 M 20.3 M 13 M 14.2 M 10.3 M 9.11 M

Gross Profit

84.3 M 68.2 M 55.5 M 32.1 M 32.5 M 34.4 M 42.5 M 43.5 M 50.1 M 62.3 M 39.1 M 22.3 M 18.9 M 22.6 M 21 M

Operating Income

7.28 M -12.1 M -10.2 M -6.76 M -3.85 M -751 K -2.25 M -60.1 M -37.8 M -7.55 M -12.1 M -6.26 M -9.01 M -4.94 M -6.45 M

Interest Expense

3.67 M 4.16 M 2.94 M 1.69 M 995 K 5.98 M 5.77 M 10.1 M 14.7 M 12.3 M 7.73 M 5.66 M 4.65 M 1.86 M 1.16 M

EBITDA

12.5 M -7.85 M -6.98 M -5.46 M -2.52 M 1.33 M -2.2 M -3.28 M -8.18 M -1.2 M -5.43 M -5.08 M -7.9 M -4.54 M -5.7 M

Operating Expenses

77 M 80.3 M 65.6 M 38.9 M 36.3 M 35.1 M 44.8 M 50.9 M 63.8 M 68.4 M 48.3 M 27.6 M 27.2 M 27.6 M 27.5 M

General and Administrative Expenses

29.4 M 28.7 M 25.8 M 15.5 M 14.4 M 13.5 M 17.9 M 13 M 15.3 M 16 M 13.2 M 9.02 M 10.8 M 11.6 M 8.23 M

All numbers in USD currency

Quarterly Income Statement Xtant Medical Holdings

2025-Q3 2025-Q2 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

140 M 139 M 139 M 135 M 130 M 130 M 130 M 128 M 109 M 109 M 109 M 93.3 M 87.3 M 87.2 M 87.1 M 86.8 M 86.7 M 81.2 M 77.6 M 13.2 M 13.2 M 13.2 M 13.2 M 13.2 M 13.2 M 13.2 M 13.2 M 13.2 M 13.1 M 7.48 M 1.51 M 1.51 M 1.51 M 1.49 M 1.44 M 12.2 M 12.1 M 11.9 M 11.9 M 10.4 M 7.14 M 6.69 M 6.68 M 6.23 M 5.51 M 5.38 M 5.34 M 5.16 M 4.53 M 42.9 M 42.9 M 42.8 M 42.7 M 41.5 M 40.8 M 39.6 M 38.2 M 37.3 M

Net Income

1.31 M 3.55 M - -5.02 M -3.86 M -4.4 M - 9.23 M -2.19 M -2.08 M - -2.35 M -1.71 M -2.21 M - -1.8 M -733 K -29 K - -1.36 M -2.46 M -2.49 M - -1.88 M -1.94 M -2.8 M - -3.15 M -5 M -5.25 M - -8.51 M -9.69 M -5.78 M - -4.9 M -4.46 M -5.6 M - -6.69 M -2.9 M -4.18 M - -1.17 M -1.9 M -4.14 M - -4.38 M -2.48 M -1.67 M - -2.52 M 731 K -1.05 M - -3.16 M -405 K 4.92 M

Revenue

33.3 M 35.4 M - 27.9 M 29.9 M 27.9 M - 25 M 20.2 M 17.9 M - 14.5 M 15.3 M 13 M - 13.8 M 15 M 12.5 M - 14 M 10.5 M 14.8 M - 15.7 M 15.3 M 16.7 M - 17.3 M 18.7 M 17.9 M - 19.8 M 21.4 M 22.1 M - 23.1 M 21.5 M 21 M - 17.7 M 9.89 M 9.5 M - 8.45 M 8.88 M 8.91 M - 7.93 M 8.27 M 8.62 M - 8.88 M 8.21 M 7.77 M - 7.54 M 7.51 M 5.87 M

Cost of Revenue

11.3 M 11.1 M - 11.6 M 11.4 M 10.6 M - 9.68 M 7.77 M 7.41 M - 6.57 M 6.9 M 5.4 M - 6.59 M 5.46 M 4.45 M - 4.77 M 3.98 M 5.16 M - 5.31 M 5.36 M 5.91 M - 5.74 M 6.27 M 5.7 M - 8.42 M 7.88 M 7.18 M - 7.11 M 6.76 M 6.88 M - 6.04 M 3.38 M 3.47 M - 3.02 M 3.29 M 3.41 M - 3.32 M 3.57 M 3.12 M - 2.6 M 2.33 M 1.86 M - 1.32 M 1.74 M -

Gross Profit

22 M 24.3 M - 16.3 M 18.6 M 17.3 M - 15.3 M 12.5 M 10.5 M - 7.9 M 8.37 M 7.56 M - 7.19 M 9.52 M 8.09 M - 9.25 M 6.55 M 9.61 M - 10.4 M 9.91 M 10.8 M - 11.5 M 12.5 M 12.2 M - 11.4 M 13.5 M 14.9 M - 16 M 14.7 M 14.1 M - 11.7 M 6.52 M 6.03 M - 5.44 M 5.59 M 5.5 M - 4.61 M 4.69 M 5.5 M - 6.28 M 5.88 M 5.91 M - 6.22 M 5.77 M 5.01 M

Operating Income

2.54 M 4.62 M - -3.78 M -2.95 M -3.47 M - -3.38 M -1.39 M -1.58 M - -1.9 M -1.3 M -1.83 M - -1.44 M -491 K -5 K - 760 K -387 K -1.36 M - -705 K -563 K -668 K - -1.44 M -2.26 M -1.66 M - -4.68 M -6.35 M -2.57 M - -1.9 M -2.12 M -2.36 M - -4.88 M -1.38 M -1.73 M - -1.25 M -1.33 M -1.19 M - -2.35 M -1.87 M -1.23 M - 213 K -347 K -1.27 M - -1.57 M -280 K -1.94 M

Interest Expense

-16 K 1 M - -13 K 992 K 835 K - 760 K 786 K 575 K - 440 K 397 K 359 K - 329 K 199 K 1 K - 2.1 M 2.05 M 1.11 M - 1.18 M 1.3 M 2.02 M - 1.79 M 2.82 M 3.54 M - 3.81 M 3.33 M 3.4 M - 3.16 M 2.98 M 2.83 M - 2.11 M 1.38 M 1.44 M - 1.5 M 1.44 M 1.28 M - 1.2 M 1.17 M 1.06 M - 868 K 266 K 171 K - 541 K 133 K 372 K

EBITDA

3.24 M 5.42 M - -3.08 M -2.45 M -2.46 M - -2.88 M -991 K -1.1 M - -1.5 M -1 M -1.55 M - -404 K -191 K 370 K - 2.42 M 766 K -678 K - 1.63 M 996 K 108 K - 3.51 M 966 K -71 K - 2.75 M -2.18 M -496 K - 3.65 M 1.53 M -583 K - -2.48 M -936 K -1.5 M - -752 K -986 K -1.02 M - -1.76 M -1.47 M -1.03 M - 790 K 55.9 K -1.06 M - -762 K 42 K -1.64 M

Operating Expenses

19.5 M 19.7 M - 20.1 M 21.5 M 20.8 M - 18.7 M 13.8 M 12.1 M - 9.8 M 9.67 M 9.39 M - 8.64 M 10 M 8.1 M - 8.49 M 6.94 M 11 M - 11.1 M 10.5 M 11.5 M - 13 M 14.7 M 13.9 M - 16.1 M 19.9 M 17.5 M - 17.9 M 16.8 M 16.5 M - 16.5 M 7.9 M 7.76 M - 6.69 M 6.93 M 6.69 M - 6.96 M 6.56 M 6.73 M - 6.07 M 6.23 M 7.18 M - 7.79 M 6.05 M 6.95 M

General and Administrative Expenses

7.07 M 7.48 M - 7.49 M 7.71 M 7.78 M - 7.14 M 4.95 M 4.88 M - 3.73 M 3.8 M 3.97 M - 3.11 M 4.17 M 3.03 M - 3.04 M 2.93 M 4.32 M - 4.23 M 4.19 M 4.48 M - 3.12 M 3.5 M 3.02 M - 3.33 M 4.53 M 4.13 M - 3.77 M 3.9 M 3.48 M - 3.98 M 2.4 M 2.43 M - 2.28 M 2.09 M 2.29 M - 2.73 M 2.09 M 2.57 M - 2.44 M 2.32 M 2.59 M - 2.15 M 1.51 M 2.39 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Xtant Medical Holdings XTNT
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Xtant Medical Holdings plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Align Technology Align Technology
ALGN
$ 173.14 -0.8 % $ 13 B usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 12.17 -0.41 % $ 1.64 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 10.9 -1.54 % $ 1.64 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Bio-Rad Laboratories Bio-Rad Laboratories
BIO
$ 279.25 0.63 % $ 7.88 B usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 3.3 -1.79 % $ 124 M franceFrance
Bruker Corporation Bruker Corporation
BRKR
$ 37.59 -1.03 % $ 5.6 K usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 61.79 0.83 % $ 91.5 B usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.61 0.84 % $ 38 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 8.68 -3.12 % $ 246 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Electromed Electromed
ELMD
$ 24.12 -1.19 % $ 204 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Helius Medical Technologies Helius Medical Technologies
HSDT
$ 1.89 - $ 1.15 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Inogen Inogen
INGN
$ 6.33 -4.95 % $ 168 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 1.0 -3.86 % $ 16.9 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 15.97 0.19 % $ 375 M usaUSA
Globus Medical Globus Medical
GMED
$ 90.42 -1.07 % $ 12.2 B usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 62.78 -0.93 % $ 3.42 B britainBritain
LENSAR LENSAR
LNSR
$ 5.7 4.4 % $ 68.2 M usaUSA
Butterfly Network Butterfly Network
BFLY
$ 4.11 -0.96 % $ 870 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Delcath Systems Delcath Systems
DCTH
$ 10.04 1.62 % $ 360 M usaUSA
Inspire Medical Systems Inspire Medical Systems
INSP
$ 54.02 -4.71 % $ 1.59 B usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 36.74 -0.51 % $ 1.14 B usaUSA
Myomo Myomo
MYO
$ 0.69 -1.43 % $ 28.9 M usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 85.11 -1.8 % $ 2.96 B usaUSA
FONAR Corporation FONAR Corporation
FONR
$ 18.68 0.38 % $ 122 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA